You can buy or sell AGLE and other stocks, options, ETFs, and crypto commission-free!
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. Read More The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX. The listed name for AGLE is Aeglea BioTherapeutics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 5, Pre-Market